Kambi Group plc Q3 Report 2016 Malta, 2 November 2016

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Kambi Group plc Q3 Report 2016

Malta, 2 November 2016

Q3 Report 2016 (unaudited)

  Financial Summary

  • Revenue amounted to €14.8 (12.8) million for the third quarter of 2016, an increase of 15%, and €41.7 (33.5) million for the period January to September 2016
  • Operating profit (EBIT) for the third quarter of 2016 was €3.1 (2.5) million, with a margin of 21% (19%), and €7.0 (4.1) million for the period January to September 2016, with a margin of 17% (12%)
  • Profit after tax amounted to €2.7 (2.1) million for the third quarter of 2016, and €6.3 (3.3) million for the period January to September 2016
  • Earnings per share for the third quarter of 2016 were €0.092 (0.071), and €0.211 (0.109) for the period January to September 2016
  • Cash flow from operating and investing activities (excluding working capital) amounted to €1.6 (2.2) million for the third quarter of 2016, and €3.1 (3.4) million for the period January to September 2016

Key Highlights

  • Solid operator turnover growth of 37% year-on-year
  • Outstanding results from Euro 2016 tournament
  • Partnership with NOVOMATIC Lottery Solutions to jointly provide sports betting powered by Kambi
  • The contract with Spanish operator Luckia is coming to an end and will not be renewed

"I am really pleased to deliver an excellent set of results for Q3. Our unparalleled service drove a 37% growth in operator turnover, which led to strong results for Kambi of 25% growth in operating profit.

I am highly encouraged by the partnership we have signed with the prestigious gaming company NOVOMATIC Lottery Solutions, where we are joining forces to create a state-of-the-art omni-channel solution for government regulated lotteries, which is a key target segment for Kambi. This partnership strengthens our outreach to potential clients in the lottery sector.

Part of our growth strategy is to build on our retail offering. We have seen tangible results as our retail service is being rolled out in several regions and is gaining momentum. " says Kristian Nylén, CEO of Kambi.

You are invited to participate in a report presentation at 10:45 CET with the CEO Kristian Nylén and CFO David Kenyon. The presentation will be held in English via a telephone conference and can also be accessed via an audiocast using the link below. Questions can be asked on the telephone conference or sent via the audiocast link.

SE: +46 8 5664 26 64         UK: +44 20 3008 9811       ES: +34 9 1414 07 82         US: +1 8 558 315 944

Link to the audiocast: https://wonderland.videosync.fi/2016-11-02-ka...-q3-report

    About Kambi

Kambi Group plc is a B2B supplier of managed sports betting services on a proprietary software platform, providing premium turnkey sports betting services to gaming operators. Kambi's product encompasses a broad offering from front end through to odds compiling and risk management. The company's current coverage includes more than 165,000 live betting events and 300,000 pre-match events per year covering 65 different sports from all over the world. Kambi utilises a best of breed security approach, with guiding principles from ISO 27001. Kambi is eCOGRA certified. Kambi Group plc is listed on First North at Nasdaq Stockholm under the symbol "KAMBI". Kambi's Certified Advisor is Redeye AB.

Kambi utilises a best of breed security approach, with guiding principles from ISO 27001. Kambi is eCOGRA certified. Kambi Group plc is listed on First North at Nasdaq Stockholm under the symbol "KAMBI". The Company's Certified Advisor is Redeye AB.

Disclaimer: The information in this report/press release is such that Kambi Group plc is required to disclose under the Swedish Securities Market Act. 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Triumph Financial Sets Stage for Q4 Earnings and Insights

Updated Category News Views 196

Triumph Financial Plans Fourth Quarter Earnings Release Triumph Financial, Inc. (Nasdaq: TFIN) recently announced its anticipation for the release of fourth quarter financial results. This event is scheduled to take place after the market closes on an upcoming Wednesday. Along with the financial report, the company will provide management commentary for stakeholders and...

Continue Reading
Monitoring ABA Therapy Progress: A Parent's Guide

Updated Category News Views 6

The Nuts and Bolts of Progress Monitoring You've got a situation in Leominster where parents are trying to make sense of ABA therapy's impact on their kids. Rob Shapiro, a big name in the ABA world, breaks it all down in a HelloNation article. We're talking about precise data collection being the backbone of measuring progress in ABA therapy. This ain't no place for...

Continue Reading
Understanding Dowlais Group's Recent Market Activities

Updated Category News Views 185

Public Disclosure Regarding Dowlais Group's Trading Activity FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code 1. KEY INFORMATION (a) Name of exempt principal trader: Investec Bank plc (b) Name of offeror/offeree in relation to whose r

Continue Reading
OFS Credit Company Reports Impressive Q4 Financials for 2024

Updated Category News Views 98

OFS Credit Company Delivers Strong Q4 2024 Financial Results OFS Credit Company, Inc. (NASDAQ: OCCI), a notable investment firm focusing on collateralized loan obligation (CLO) equity and debt securities, has announced its financial performance for the fiscal quarter ending October 31, 2024. This report outlines the company’s significant financial growth and strategic...

Continue Reading
Breakthrough Data on HBI-8000 and Nivolumab for Melanoma

Updated Category News Views 89

HBI-8000 and Nivolumab: A New Era in Melanoma Treatment Recent findings highlight the potential of HBI-8000 in combination with nivolumab, suggesting a transformative approach in the treatment of advanced melanoma. This promising combination will be discussed in detail at an upcoming prestigious annual meeting focused on advancements in immunotherapy. Innovative Solutions...

Continue Reading